Navigation Links
Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
Date:8/19/2007

VALLEY COTTAGE, New York, August 15 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL), a biopharmaceutical company engaged in the acquisition, development and commercialization of therapeutics for the treatment of unmet medical needs, particularly neuropathic pain and hepatitis C, today announced its has posted to shareholders a notice convening its AGM and EGM. The AGM and EGM will take place at the Conference Room at the Company's Israeli offices at Building 3, Kiryat Weizmann Science Park, Rehovot, Israel 76100, at 4:00 p.m. Israel time, and 4:30pm Israel time, respectively, on September 25, 2007.

At the AGM it is proposed that:

- the annual reports for the year ended 31 December 2006 be received;

- Kesselman & Kesselman (PricewaterhouseCoopers) be reappointed as the Company's auditors and the fixing of their remuneration be authorized; and

- Messrs Michael Weiss, Ben Zion Weiner and William Kennedy be re-appointed as Directors of the Company.

At the EGM it is proposed that:

- the registered share capital of the Company be increased from 300,000,000 Ordinary Shares to 500,000,000 Ordinary Shares, NIS 0.02 nominal value each; and

- the listing of the Company's Ordinary Shares on the Official List of the United Kingdom Listing Authority be cancelled.

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development and commercialization of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of neuropathic pain. XTL is also developing several novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Contact:

Ron Bentsur, Chief Executive Officer

Tel: +1-845-267-0707 ext. 225

+972-8-930-4444


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd

Copyright©2007 PR Newswire.

Related biology technology :

1. NameProtect releases annual list of top trademarkers
2. Doyle says new contracts saving state more than $16 million annually
3. Department of Commerce offers up to $1 million annually to aid tech entrepreneurs
4. Annual Bioethics Forum to explore genetic testing
5. Annual Conference Honors Tech Grant Winners
6. General Notes on Primer Design in PCR*
7. General Considerations for Successful Transfection Experiments
8. Real-Time PCR: General Considerations, Rev A
9. AG accuses BioCATT of violating meetings law
10. VC trends, company progress discussed at Mason Wells portfolio meeting
11. Beware the Dreaded Off-Site Technology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... ... firm is utilizing its extensive experience with Health Economics and Outcomes Research (HEOR) ... Health Record data. In 2014, US healthcare spending exceeded $3.0 trillion with nearly ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... Today Aether ... a project, funded by a Bill and Melinda Gates Foundation grant, to ... Bill & Melinda Gates Foundation, also known as the Gates Foundation, is said to ...
(Date:8/18/2017)... ... August 18, 2017 , ... OAI, a ... MEMS, and Microfluidics Industries, announces the new Model 800E front and backside, semi-automatic ... automated production mask aligners. OAI has already received and installed several orders ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... cancer research and personalized medicine, today announced the launch of a new breast ... Missouri. The study’s goal is to evaluate the potential for early detection of ...
Breaking Biology Technology:
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
Breaking Biology News(10 mins):